Prevention of death in COPD.

[1]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[2]  K. Rabe.  Treating COPD--the TORCH trial, P values, and the Dodo. , 2007, The New England journal of medicine.

[3]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[4]  J. Cornuz,et al.  Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? , 2006, Thorax.

[5]  N. Anthonisen,et al.  Inhaled corticosteroids and mortality in COPD. , 2006, Chest.

[6]  C. Marquette,et al.  Pulmonary Embolism in Patients with Unexplained Exacerbation of Chronic Obstructive Pulmonary Disease: Prevalence and Risk Factors , 2006, Annals of Internal Medicine.

[7]  D. Postma,et al.  Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease , 2005, Thorax.

[8]  D. Halpin.  Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis , 2005, International journal of clinical practice.

[9]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[10]  D. Tashkin,et al.  Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. , 2003, Chest.

[11]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[12]  P. Barnes.  Reduced histone deacetylase in COPD: clinical implications. , 2006, Chest.

[13]  E. Robin,et al.  The diagnosis of pulmonary embolism. When will we ever learn? , 1995, Chest.